Coherus BioSciences Announces New Employment Inducement Grants
April 05 2022 - 4:30PM
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq:
CHRS), today announced that effective March 31, 2022, the
compensation committee of the Company’s board of directors granted
options to purchase an aggregate of 461,000 shares of the common
stock of the Company to newly hired employees with a per share
exercise price of $12.91, the closing trading price on the grant
date. One Chief level executive was granted options to purchase
200,000 shares as well as 50,000 restricted stock units. 18
non-officer employees were granted options to purchase an aggregate
of 261,000 shares.
The stock options and RSUs were granted pursuant to the Coherus
BioSciences, Inc. 2016 Employment Commencement Incentive Plan,
which was approved by the Company’s board of directors in June 2016
under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity
grants to induce new employees to enter into employment with the
Company.
Coherus BioSciences Contact Information:
IR ContactMcDavid StilwellCoherus BioSciences,
Inc.IR@coherus.com
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Sep 2023 to Sep 2024